Long-term Registry of Patients Treated With Loncastuximab Tesirine
Retrospective and prospective multi-center observational study of patients with B-cell lymphomas treated with loncastuximab tesirine treatment in real-world practice.
B-Cell Lymphomas
Progression-free Survival (PFS), Up to 48 Months|Overall Survival (OS), Up to 48 Months|Duration of Response (DoR), Up to 48 Months|Overall Response Rate (ORR), Up to 48 Months|Time to Partial Response (PR), Up to 48 Months|Time to Complete Response (CR), Up to 48 Months|Time to Disease Progression, Up to 48 Months|Number of Patients with Adverse Events, Includes serious adverse events (SAEs) and adverse events (AEs) Grade 3 or higher for the events of: edema, myelosuppression, infections, and cutaneous reactions., Up to 48 Months
Number of Hospitalizations, Up to 48 Months|Duration of Hospitalizations, Up to 48 Months|Reasons for Hospitalizations, Up to 48 Months|Number of Surgeries, Up to 48 Months|Type of Surgeries, Up to 48 Months|Reasons for Surgeries, Up to 48 Months|Number of Emergency Room Visits, Up to 48 Months|Reasons for Emergency Room Visits, Up to 48 Months|Number of Outpatient Visits, Up to 48 Months|Reasons for Outpatient Visits, Up to 48 Months
The purpose of this study is to assess treatment patterns and generate evidence on the effectiveness and safety of loncastuximab tesirine treatment in real-world practice. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).